Show simple item record

dc.contributor.authorBrekke, Kurt R.
dc.contributor.authorDalen, Dag Morten
dc.contributor.authorStraume, Odd Rune
dc.date.accessioned2022-04-05T09:13:33Z
dc.date.available2022-04-05T09:13:33Z
dc.date.issued2022-03
dc.identifier.issn0804-6824
dc.identifier.urihttps://hdl.handle.net/11250/2989856
dc.description.abstractWe study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework that allows us to capture the informational role of biomarkers and their effects on price competition and treatment choices. Although biomarkers increase the information available to prescribers, we identify an anticompetitive effect on the prices set by producers of therapeutically substitutable drugs. We also nd that better information about each patient s most therapeutically appropriate drug does not necessarily lead to more efficient treatment outcomes.en_US
dc.language.isoengen_US
dc.relation.ispartofseriesSAM DP;06/2022
dc.titleCompeting with precision: incentives for developing predictive biomarker testsen_US
dc.typeWorking paperen_US
dc.source.pagenumber47en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record